AI Analysis
AI-generated analysis. Always verify with the original filing.
Kazia Therapeutics Limited reported a half-year loss after tax of AUD 12,552,490 for the period ended 31 December 2025, compared to AUD 10,453,811 in the prior period, with cash reserves of AUD 69,459,980 following a US$46.51 million net PIPE financing. The company provided updates on paxalisib clinical progress in breast cancer and regained Nasdaq compliance.
Key Takeaways
1Net loss after tax AUD 12,552,490 for half-year ended 31 December 2025 (vs. AUD 10,453,811 at 31 December 2024)
2Cash and cash equivalents AUD 69,459,980 at 31 December 2025
3PIPE private placement on 2 December 2025 raised US$46.51 million net proceeds
4Regained Nasdaq compliance with Listing Rule 5550(b) on 18 December 2025
5Net current asset position AUD 45,612,689 at 31 December 2025
6Paxalisib Phase 1b study in metastatic TNBC reported >50% CTC reduction on 10 July 2025